A new test lets doctors more accurately identify the right antibiotics to treat serious, chronic infections that are biofilm based. For people with cystic fibrosis, that’s good news.
More than 80 per cent of infections are caused by biofilms. This new breakthrough test,
bioFILM PATM, is of immense significance to the medical community.
![]() |
Agress® is a novel seed treatment developed by Innovotech that is currently going through registration in the USA and Canada.
Agress™ is a novel seed treatment developed by Innovotech that is currently going through registration in the USA and Canada. It is designed for use initially in pulse crops (such as dry beans and soybeans) as a bactericide and fungicide. Using silver, which naturally occurs in the environment at levels above those used in Agress™, the seed treatment is environmentally friendly while demonstrating superior efficacy. Currently developed as a seed treatment, the use of Agress™ is being expanded to fit a host of needs across the agriculture sector.
![]() |
|
Innovotech solves client biofilm problems through its Contract Research department. We have a track record of both standardized and customized research to meet client needs.
The scope of research is from early stage identification of problems and screening of agents for "anti-biofilm activity”, to research acceptable to regulatory agencies for product claim validation, to post-market product comparisons for marketing purposes.
Innovotech regularly develops in vitro models of the client specific situation as a starting point that enables any number of test parameters to be tested
New Silver Technology Kills Biofilms
January 10, 2012,
Innovation Anthology
The Cutting Edge: Where BioMed and BioTech Intersect
September 28, 2011
World Talk Radio website
"Innovotech product wins international seal of approval",
April 21, 2011
Edmonton Journal